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Abstract
Human chorionic gonadotrophin (hCG) is released from placental trophoblasts and is involved in
establishing pregnancy by maintaining progesterone secretion from the corpus luteum. Serum hCG
is detected in the maternal circulation within the first 2–3 wks of gestation and peaks at the end of
the first trimester before declining. In Down's syndrome (DS) pregnancies, serum hCG remains
significantly high compared to gestation age-matched uncompromised pregnancies. It has been
proposed that increased serum hCG levels could be due to transcriptional hyper-activation of the
CGB (hCG beta) gene, or an increased half life of glycosylated hCG hormone, or both. Another
possibility is that serum hCG levels remain high due to reduced availability of the hormone's
cognate receptor, LHCGR, leading to lack of hormone utilization. We have tested this hypothesis
by quantifying the expression of the hCG beta (CGB) RNA, LHCGR RNA and LHCGR proteins in
chorionic villous samples. We demonstrate that chorionic expression of hCG beta (CGB) mRNA
directly correlates with high serum hCG levels. The steady-state synthesis of LHCGR mRNA (exons
1–5) in DS pregnancies was significantly higher than that of controls, but the expression of full-
length LHCGR mRNA (exons 1–11) in DS was comparable to that of uncompromised pregnancies.
However, the synthesis of high molecular weight mature LHCGR proteins was significantly reduced
in DS compared to uncompromised pregnancies, suggesting a lack of utilization of circulating hCG
in DS pregnancies.
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The incidence of aneuploidy in human pregnancies is
unusually high (1–2%) compared to other mammals [1].
Monosomies and trisomies together account for 35% of
clinically detected spontaneous abortions (6–20 wks of
gestation), stillbirth (4%) and most importantly, are the
leading cause of developmental disability and mental
retardation of those surviving such pregnancies [2-4]. Of
all the genetically compromised pregnancies, Down's syn-
drome (Trisomy 21, T21) is the most frequent (1/700 live
births [5]). The Edward's (Trisomy 18, T18) and Pautau's
(Trisomy 13, T13) syndromes are considered relatively
rare pregnancy disorders with a prevalence at birth of 1 in
7000 and 29000, respectively [6,7].
Genetically, 89–95% of Down's syndrome (DS) patients
carry an extra chromosome 21 (chr 21) which arises due
to meiotic nondysjunction and is usually inherited from
the mother [1]. About 1–2% of DS patients have genetic
mosaicism (nondysjunction following fertilisation in
early embryos), while 3–4% of cases are due to transloca-
tion of chr 21 to another autosome, usually chr 14 [8]. In
addition to the characteristic variability in mental retarda-
tion, physical and facial features, congenital heart and gas-
tro-intestinal defects, the DS patients are also susceptible
to leukaemia and Alzheimer's-like dementia [9-11].
The chromosomal abnormalities in DS and other trisomic
pregnancies are very often associated with increased or
reduced levels of proteins, growth factors and hormones
in the maternal blood compared to those of normal preg-
nancies. For example, in DS pregnancies (11–14 wks of
gestation), the serum human chorionic gonadotrophin
beta (hCG-β) and pregnancy-associated plasma protein-A
(PAPP-A) concentrations tend to be high and low, respec-
tively [12].
Human chorionic gonadotrophin (hCG) is the key repro-
ductive hormone regulating human pregnancy. It is a
member of the family of glycoprotein hormones that
includes luteinizing hormone (LH), follicle stimulating
and thyroid stimulating hormones, each member of
which functions through the formation of a non-covalent
heterodimer from two subunits, α and β.
In human placenta hCG is primarily produced by syncy-
totrophoblasts and to a certain extent by extravillous
cytotrophoblasts [13]. One of the earliest endocrine roles
of hCG is to sustain the corpus luteum which must pro-
duce enough progesterone to establish pregnancy at the
outset. In addition, hCG facilitates trophoblast differenti-
ation, remodeling of the uterine epithelium and stroma
(decidualization) and endometrium for implantation,
invasion of the maternal spiral arterioles, and angiogen-
esis by acting on vascular smooth muscle and endothelial
cells [14]. In normal pregnancies, detectable levels of hCG
begin to appear in the maternal circulation at about 2–3
wks after conception, and reach their peak at ~11–13 wks
before declining significantly in the later stages of preg-
nancy. Indeed, high serum hCG levels at mid-late preg-
nancy have been associated with pre-eclampsia, intra-
uterine growth restriction and Down's syndrome (DS)
[15-18].
The hCG hormone transduces signals by binding to its
specific LH/hCG receptor (LHCGR) expressed on surface
of the cell. Since hCG and LH receptors are identical, it is
often referred to as the LH/hCG receptor (LHCGR) and is
encoded by a single copy ~70 Kb LHCGR gene, located on
human chromosome 2p21 [19]. This receptor is structur-
ally very similar to two other hormone receptors (thyroid
stimulating and follicle stimulating hormone receptors).
The LHCGR gene has 11 exons and codes for multiple
alternatively spliced species (at least 6) of mRNA. These
different mRNA transcripts are initiated at multiple sites
spanning a region more than a kilobase upstream of the
first exon [20].
On the basis of structure and topology, LHCGR is a mem-
ber of the rhodopsin/β-adrenergic receptor superfamily of
G protein-coupled receptors. Agonist (hormone) binding
to LHCGR allows dissociation of membrane-bound cog-
nate G proteins that regulate phospholipase C, adenylyl
cyclase and ion channels which in turn control cellular
inositol phosphates, cAMP, Ca+2 and other secondary
messengers [21,22].
LHCGR is a 701 amino acid residue protein containing
three distinct domains: an unusually large (340 residues)
N-terminal extracellular domain which binds hCG, a ser-
pentine transmembrane (TM) region containing seven
TM repeats connected by three extra- and intracellular
loops, and a C-terminal tail. The predicted relative molec-
ular mass (Mr) is ~75 K, or higher, depending upon the
level of glycosylation [23].
Moreover, alternatively spliced mRNAs produce several
truncated intra-cellular protein isoforms which have lig-
and binding capacity but are ineffective in transducing sig-
nals [24]. The functional significance of all isoforms
remains to be established. However, the accessibility of
the Mr 85–95 K species to surface biotinylation, protease
and glycosidase (neuraminidase), suggests that they have
ligand binding and signal transduction capacities. On the
other hand, the Mr 65–75K proteins contain high-man-
nose type side chains which are susceptible to endogly-
cosidase H, and are immature and intracellular [25-27].
The high relative molecular mass 165–200K group is
thought to be a dimer of the mature functional receptor
[28]. Interestingly, smaller species of LHCGR proteins (MrPage 2 of 14
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with cDNAs [25-27,29].
Natural missense [30] and deletion mutations [31] of the
human LH receptor have been reported to be associated
with elevated serum LH levels in these patients. Similarly,
the circulating LH concentration remains high [32,33] in
mice carrying a homozygous deletion of Lhr gene (Lhr-/-).
Moreover, the lack of functional cytokine receptor expres-
sion, due to natural mutations of the IFN-γ receptors 1
and 2, has been directly linked to high serum IFN-γ levels
in patients suffering from infectious diseases [34,35].
These reports prompted us to investigate whether
increased serum hCG levels in DS pregnancies could be
linked to the expression of its functional receptor in chor-
ionic villi.
Materials and methods
Placental tissues and chorionic villous samples
This study was approved by the local ethics committee of
King's College Hospitals, London, UK and written consent
was obtained from patients before the collection of sam-
ples. Placental tissue was obtained from patients undergo-
ing termination of pregnancy with gestational age range of
7–12 wks, after vaginal delivery or caesarian section. Cho-
rionic villous samples (CVS) were collected in a Petri dish
and material not required for genetic analysis was washed
in Ca+2/Mg+2-free PBS (Invitrogen, Carlsbad, CA, USA)
and stored in 500 µl RNA Later (Ambion, Huntingdon,
UK), held at 4 C overnight before long term storage at -
20°C.
RNA extraction and cDNA synthesis
Depending upon the availability, up to 30 mg of CVS was
extensively washed in PBS, homogenized in 500 µl Trizol
(Invitrogen) with a tissue grinding pestle (Anachem, UK).
Subsequent RNA extraction, DNase I treatment (Sigma, St
Louis, MO, USA), cDNA synthesis were exactly as
described previously [36,37]. In some cases, a Qiagen
RNA extraction kit (Qiagen, West Sussex, UK) was used
and RNA was stored at -70°C in water or ethanol.
Quantitative PCR
Quantitative PCR was performed using the Light Cycler
RNA amplification system in glass capillaries and a fluo-
rescence-based hybridization detection format (Roche
Diagnostics GmbH, Mannheim, Germany) as described
[38]. Briefly, the assays were carried out in duplex where
both the experimental sample and an internal control
(ACTB and HPRT) were run in the same reaction. The
reporters LC-Red 640 and LC-Red 705 were employed to
generate hybridization probes for experimental and inter-
nal controls and the amplification for each cDNA was
recorded by dual color detection. A color compensation
file was created according to the manufacturer instruc-
tions (Roche Diagnostics) and was compensated for PCR
cycles in duplex during each run. In some experiments,
the control reactions were run at the same time as the test
samples under the same reaction conditions, but as single
reactions. In order to establish that there was no cross con-
tamination, negative controls (a full reaction without
cDNA) were run in each experiment.
Cross-contamination was avoided by sequentially adding
water, reaction master-mix (containing enzyme, Mg+2 and
PCR buffer; Light Cycler RNA amplification Kit, Roche
Diagnostics), and cDNA to a final volume of 10 µl. The
analysis mode set to quantification included initial dena-
turation at 95°C for 10 min followed by 40 cycles consist-
ing of the following parameters for segments 1–3: Target
temp, 95°C, 55°C and 72°C respectively; incubation
time 10, 7 and 12 sec respectively; Transition rate 20°C/
sec, 20°C/sec and 10°C/sec respectively, and a single
acquisition mode at segment 2. PCR primers, hybridiza-
tion probes and amplicon lengths are shown in Table 1.
Data were automatically collected and filtered to remove
background by the Light Cycler software which set the
crossing point for all the different reactions against the
standard curve. Data were transferred to Microsoft Excel
for further analysis.
Table 1: Quantitative PCR primers, HUGO approved gene names, GenBank accession numbers, hybridization probe sequences and 
the length of respective amplicons.
Gene Acc. No PCR Primer Hybridization Probes bp
ACTB XM_037235 F 5'-agc ctc gcc ttt gcc ga-3'
R 5'-ctg gtg cct ggg gcg-3'
5'-ttg cac atg ccg gag ccg ttg-FL-3'
5'-LC Red 705-cga cga cga cgc cgg cga tat c-Ph-3'
178
HPRT M31642 F 5'-atc aga ctg aag agc tat tgt aat gac ca-3'
R 5'-tgg ctt ata tcc aac act tcg tg-3'
5'-aga ctt tgc ttt cct tgg tca ggc agt-FL-3'
5'-LC Red 705-aat cca aag atg gtc aag gtc gca agc-Ph-3'
230
CGB (hCG β) NM_000737 F 5'-gac gca cca agg atg gag at-3'
R 5'-gcg gta gtt gca cac cac ct-3'
5'-gtg tgc atc acc gtc aac acc acc-FL-3'
5'-LC Red 640-tct gtg ccg gct act gcc cca c-Ph-3'
251
LHCGR Ex 1–5 NM_000233 F 5'-tcg act atc act tgc cta cc-3'
R 5'-gga gaa gac ctt cgt aac at-3'
5'-ttt gtc tga aat act gat cca gaa cac ca-FL-3'
5'-LC Red 640-aat ctg aga tac att gag ccc gc-Ph-3'
291
LHCGR Ex 11 F 5'-act tcc tta ggg tcc tg-3'
R 5'-gtg atg acg gtg agg g-3'
5'-ggc tct atc tgc tgc tca tag c-FL-3'
5'-LC Red 640-cag ttg att ccc aaa cca agg g-Ph-3
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electrophoresis and Western blots
The HEK-293 cell line expressing N-terminal 362 amino
acid residues of human LHCGR was kindly provided by
Professor Axel Themmen, Erasmus Universty, Rotterdam,
The Netherlands. The expression vector contained LHR
extracellular domain (ECD, 1–362) fused to a tag peptide
(YPYDVPDYA) from the hemagglutinin 1 (HA1) epitope
of influenza virus and tetracycline (tet)-inducible pro-
moter. Cells were grown exponentially in tet-free fetal
bovine serum prior to overnight induction with tetracy-
cline as recommended.
Protein extraction from cultured cells, placental villous
tissues with T-PER (Perbio, Helsinborg, Sweden) and
from CVS, following Trizol lysis were exactly as described
previously [36] except the 50 mM Tris-HCl, pH 8.0 buffer
was replaced by 25 mM HEPES-OH, 8.0. The total protein
concentration in each extract was measured in duplicate
(Lowry assay; BioRad DC substrates, BioRad, Hemel
Hempstead, UK). Based on this estimate, approximately,
10–20 µg of total protein was loaded in each lane; for each
CVS sample it was 10 µg per lane. The separation of pro-
teins by SDS-polyacrylamide gels and Western blot analy-
sis were as described [36-38]. Both 1% casein and 1%
non-fat milk were equally effective blocking agents in
Western blots.
The primary and secondary antibodies used were as fol-
lows: murine control IgG (Sigma) at a concentration of 1
µg/ml, protein A-sepharose purified anti-human LHCGR
mouse monoclonal antibody (LHR-29) at a concentration
1 µg/ml, anti -β Actin, clone AC-15 (Sigma) and goat anti-
mouse IgG (H+L) HRP-conjugated (Chemicon Interna-
tional Inc., CA, USA) at dilutions of 1 in 2000 and 1 in
5000, respectively.
Hormone assays
Patient information and consent forms were given to each
patient who came for ultrasound scan at HBRC, King's
College Hospital. The venous blood (5 + 5 ml) was col-
lected from those who consented (at 12–14 wks of gesta-
tion) with and without anticoagulant. Sera and plasma
obtained by centrifugation (1500 rpm, 10 min at 4 °C)
were aliquoted and stored at -20 °C.
Free hCG β and intact hCG were measured using the
Brahms Kryptor (Brahms AG, Berlin, Germany) random
continuous access immunoassay analyzer by a time
resolved amplified cryptate fluorescence emission
method. The performance of these methods have been
described previously [39,40].
Densitometry and data analysis
Densitometry of autoradiograms was carried out using a
1D-Multi Lane Densitometry program in an AlphaImager
(1220v5.5, Alpha Innotech Corp. San Leandro, CA, USA)
as described [36-38]. Scan data (experimental and β-actin
control) were transferred to Microsoft Excel where the
pixel density of each experimental lane was normalized to
its corresponding β-actin value. Each experiment was
repeated at least twice and average values for each data
point were plotted. The means, standard deviations, vari-
ance (anova) for each data-set were computed using Anal-
ysis ToolPak (ATP) software. Values are shown as mean +/
- SEM. A value for the level of significance (P-value) was
calculated using the Poisson statistic. P<0.05 was consid-
ered significant. In experiments, where mRNA expression
and the serum hormone concentration data were not nor-
mally distributed, the median values and 95% confidence
intervals were calculated and the Mann-Whitney non-par-
ametric U-test was employed to establish statistical
significance.
Results
The goal of this study was to examine the placental expres-
sion of the LHCGR mRNA and functional receptor protein
expression with respect to serum hCG concentrations in
Down's syndrome pregnancies. To achieve this, 1,152
CVS from high-risk pregnancies were collected. Of these,
58 were Down syndrome (DS, trisomy 21 [T21]), 22
Edwards's syndrome (trisomy 18 [T18]) and 12 were
Patau's syndrome (trisomy 13 [T13]) confirmed by bio-
chemical, molecular and cytogenetic analyses. The
number of samples that contained sufficient tissue for
RNA analysis was 41 for T21, 14 for T18 and 7 for T13.
CGB (hCG β) and LHCGR genes are hyperactivated in 
Down's syndrome pregnancies
The hCG α subunit is synthesized in excess and is com-
mon to all members of this hormone family, whereas the
hCG β subunit, which recognizes the cognate receptor, is
specific for the hormone. Therefore, in order to evaluate
the chorionic regulation of the hormone, the expression
of hCG β mRNA synthesis was measured.
The expression of hCG β (CGB) mRNA in CVS were
assayed by quantitative real-time PCR (Q-PCR) amplifica-
tion of cDNA. Since mRNA expression values in trisomic
pregnancies exhibited a wide range of distribution, the
95% confidence interval limits and the median values in
each pregnancy conditions were determined. Such analy-
sis revealed that CGB (hCG β) gene expression in Down's
syndrome CVS was significantly higher (P <0.001) com-
pared to that of controls (Fig. 1). Moreover, hCG β (CGB)
mRNA expression levels in T18 and T13 pregnancies were
comparable to those of controls (Fig. 1).Page 4 of 14
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(exons 1–11), the coding region for extracellular domain
(ECD), hinge region, transmembrane (TM), and intracel-
lular domains (ICD) of the receptor, together with
multiple alternatively spliced isoforms [41-43] are shown
in Fig. 2a. The ECD alone has high ligand affinity [44]
whereas, the TM and ICD are necessary for signal trans-
duction [24]. The majority of isoforms exhibit deletion of
exon 9 and 11 as observed in sheep [45], pig [21,27] and
rat [46]. Deletion of coding sequences due to alternative
splicing of isoforms 1–5 maintains an open reading
frame, but in isoforms 6 and 7 frame-shift mutations are
introduced resulting in stop codons at exon 11 and the
potential production of soluble truncated receptor
[42,43].
The LHCGR mRNA (exons 1–5) expression in DS preg-
nancies was significantly higher (P= 0.0501) compared to
that of T18, T13 and uncompromised pregnancies (Fig.
2b). The CGB gene expression (Fig. 1) positively corre-
lated with LHCGR exons 1–5 mRNA synthesis (correla-
tion coefficient, r= 0.61). These results suggested that both
the CGB and LHCGR genes were hyperactivated in DS pla-
centa compared to expression levels in normal and other
trisomic (T18 and T13) pregnancies. Notably, the quanti-
tative increase in hCG β (CGB) /LHCGR mRNA produc-
tion in the T21 group of pregnancies (Figs. 1 and 2b) was
at least 3-fold higher than that observed for the T18 and
T13 CVS.
The results described above showed a significant increase
in LHCGR mRNA transcription in DS placenta compared
to that of control pregnancies. However, as noted above,
alternative splicing could give rise to mRNA variants that
may not encode the full-length functional receptor. As a
critical test of whether the quantitative increase in LHCGR
(exons 1–5) mRNA in DS placenta truly reflects full-
length receptor mRNA synthesis, the transcription of the
3' end of the gene (representing exon 11) was measured
by Q-PCR using the same set of cDNA samples. The results
(Fig. 2c) demonstrate that the chorionic expression of
exon 11 in DS is comparable to that of control pregnan-
cies, indicating that a significant population of LHCGR
mRNA in DS placenta does not contain parts of exon 11.
In further attempts to measure the full-length LHCGR
transcripts, we have tested three sets of custom-designed
primer and probe to amplify exons 10–11 by Q-PCR.
None of these were capable of amplification of LHCGR-
specific cDNA whereas β-actin, CGB,IFNGR1,IFNGR2,
LIFR and syncytin could be amplified by semiquantitative
and Q-PCR. The LHCGR exons 7–9 could be amplified by
Q-PCR from placental cDNAs obtained from early and
late pregnancies. However, the signal intensity was
reduced by at least 100-fold compared to that of exons 1–
5 or exon 11. Therefore, the amount of cDNA in CVS sam-
ples was not sufficient for either semiquantitative or Q-
PCR. To ensure that the light-cycler signals during exon 11
amplification were not due to DNA contamination,
equivalent amount of the DNase-treated mRNA (not
reverse transcribed) corresponding to experimental sam-
ples were tested. Amplification only occurred when cDNA
was added to the Q-PCR.
Serum hCG β and intact hCG (α and β) are significantly 
elevated at 11–14 wks gestation in Down's syndrome 
pregnancies
Consistent with data from previous studies [12,17,39,40],
serum hCG β levels in DS pregnancies were significantly
higher (P <0.01) compared to that of uncompromised
pregnancies. Moreover, serum hCG β levels were lowest in
T18 (P <0.01) and were significantly low in T13 (P <0.05)
compared to control serum samples (Fig. 3a). When
adjusted for gestational age, the mean serum hCG β con-
centrations in DS were between 2 and 3.6-fold higher
than those of normal pregnancies (12–14 wks). Serum
hCG β levels positively correlated (r = 0.39) with hCG β
(CGB) mRNA expression.
As noted above, the circulating hCG which transduces sig-
nals by binding to its receptor LHCGR is intact hCG het-
erodimer composed of both α and β subunits. In order to
establish the relation between the circulating ligand hCG
and its receptor expression, we next measured the hCG
heterodimer concentrations in serum from normal and
CGB (hCG β) expression in chorionic villous samples (CVS) from DS and other tr somic pregnan iesFigure 1
CGB (hCG β) expression in chorionic villous samples 
(CVS) from DS and other trisomic pregnancies. 
Quantitative PCR analysis (Table 1) of the chorionic hCG β 
(CGB) mRNA expression in control (N = 24), T21 [DS, N = 
41], T18 (N = 14) and T13 (N = 7) pregnancies. **P<0.01Page 5 of 14
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Reproductive Biology and Endocrinology 2005, 3:25 http://www.rbej.com/content/3/1/25The structure of LHCGR mRNA and expression in chorionic villous samples (CVS) from DS and other trisomic pregnanciesFigure 2
The structure of LHCGR mRNA and expression in chorionic villous samples (CVS) from DS and other tri-
somic pregnancies. a) the organization of exons 1–11 in full-length (FL) LHCGR mRNA (open boxes) and possible alterna-
tively spliced isoforms 1–7 [41-43]. The sequences deleted from the isoforms are indicated by closed boxes. Regions of mRNA 
encoding the extracellular domain (ECD), transmembrane (TM) domain, the hinge region and the intra-cellular domain (ICD) 
are shown. The regions of cDNA (exons 1–5 and exon 11) amplified by Q-PCR are indicated by bidirectional arrows. b) chor-
ionic LHCGR mRNA expression (exons 1–5) in control (N = 24), T21 [DS, N = 23], T18 (N = 8) and T13 (N = 3) pregnancies; 
c) chorionic LHCGR mRNA expression (exon 11) in control (N = 15) and T21 (N = 18) pregnancies. The median values and 
95% confidence ranges of RNA expression in each pregnancy condition are shown; N = number of patient samples analyzed. *P 
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Serum hCG β and hCG heterodimer concentrations in DS and other trisomic pregnancy conditions. a) serum 
hCG β hormone concentrations in control (N = 18), T21 (N = 23), T18 (N = 7) and T13 (N = 4) pregnancies b) serum hCG 
heterodimer concentrations in control (N = 19), T21 (N = 15), T18 (N = 12) and T13 (N = 4) pregnancies; c) serum hCG het-
erodimer concentrations at 11 wk (control, N = 417; T21 N = 68), 12 wk (control, N = 417; T21, N = 148), 13 wk (control, N 
= 161 ; T21, N = 73), and 14 wk (control, N = 65 ; T21, N = 14) pregnancies; The median hormone concentrations and 95% 
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hCG heterodimer concentrations in DS pregnancies (12–
14 wks) was significantly increased (P <0.01) compared to
that of control sera (Fig. 3b). The hCG heterodimer
concentration in T13 pregnancies was comparable to
uncompromised controls, but was significantly reduced
(P <0.01) in T18 pregnancies (Fig. 3b).
These results suggest that circulating free β hCG and intact
hCG hetrodimers are abundant at 11–14 wks of
pregnancy in DS. The data shown in Fig. 3b were obtained
from a limited number of serum samples from control (n,
18) and DS (n, 24) pregnancies predominantly at 12–14
wks of gestation. In order to further verify these data, the
hCG heterodimer concentrations at 11, 12, 13 and 14 wks
of pregnancy measured in sera from a large number of
control and DS pregnancies as part of the previous studies
[39,40] were compared. Such analysis revealed that hCG
heterodimer concentrations in DS pregnancies were sig-
nificantly higher than that of control sera at each time
point tested (Fig. 3c).
Western blot analysis to establish the specificity of the 
mouse monoclonal anti human LHR29 antibody
LHR29 monoclonal antibody was originally obtained by
immunizing mice with the purified recombinant human
receptor extracellular domain (amino acids 75–406)
expressed in Escherichia coli. The specificity of the antibody
was verified by its ability to immunoprecipitate
recombinant receptor and immunopurify 125I-hCG-recep-
tor complexes from transfected cells, western-blot analysis
with the immunogen, immunocytochemistry in cells
transfected with either the cloned receptor or a mock vec-
tor. Patterns obtained by immunohistochemistry of
human testis matched with results expected for a trans-
membrane receptor specific to Leydig cells ([47], and Axel
Themmen, personal communication). In order to further
verify the antigenic specificity of this antibody, the HEK
293 cell line expressing LHR ECD (1–362) was grown in
the presence and absence of tetracycline. Extracted pro-
teins were resolved via 8% SDS-PAGE, Western blotted,
and blots were reacted with control mouse IgG or LHR 29
monoclonal antibody. In order to ensure that equal quan-
tities of protein were transferred, the blots were stained
with coomassie brilliant blue following chemilumines-
cence detection. The results (Fig. 4a, and 4b) demonstrate
that the LHR29 monoclonal antibody specifically recog-
nizes at least three (Mr 44–48K) tet-inducible species of
LHCGR expressed in vitro (two bands appear to migrate as
doublet). These three variants possibly reflect different
levels of glycosylation. Moreover, these species (Mr 44–
48K) are also recognized by anti-HA1 antibody in Western
blots (Axel Themmen, personal communication), provid-
ing a further line of evidence that the LHR 29 antibody
reaction is specific.
Human placenta expresses at least six LHCGR protein 
variants
In order to examine the LHCGR proteins produced in
human placenta, the villous tissues obtained from 7 wk-
and 10 wk-gestational age placenta were detergent
extracted, reacted with non-specific control mouse IgG
(not shown) and LHR29 in Western blots. To further con-
trol the experiment, the extracts from HEK293 (LHR ECD)
were also incorporated and the blots were stained with
coomassie blue following chemiluminescence detection.
We detected (Fig. 5a) at least six major LHCGR variants
ranging in molecular mass (Mr) from 44K-95K (44K, 48K,
52K, 62–68K, 80K and 95K). These bands were also
detected by LHR74 which recognizes LHCGR epitopes dif-
ferent from that of LHR29, but not when the primary anti-
body was murine IgG (data not shown). The Western blot
patterns of human placental tissue obtained with LHR29
antibody were very similar to those described by VuHai-
LuuThi et al in porcine testis [27,47]. Additionally, our
results are fully consistent with the data more recently
reported by Bukovsky et al in human tissues [28] using
independent mouse monoclonal antibodies (anti-LHR
mAb clone 3B5) and in LH-induced human M17 neurob-
lastoma cells [48] using a rabbit polyclonal antibody
(raised against the N-terminal peptide sequence 15–38 of
the rat LH/CG receptor).
The chorionic villous samples (20–30 mg tissues) are not
sufficient for separate RNA and protein analysis. We have
recently described a method where RNA, DNA and
proteins can be quantitatively recovered from the same
sample by Trizol extraction [36]. The results shown in Fig
5b demonstrate that the detergent extracted LHCGR pro-
tein variants from placenta (Fig. 5a) were identical to
those observed with Trizol extracted proteins from human
placenta. Indeed, the Trizol-extracted bands were some-
what sharper than the corresponding detergent extracted
LHCGR variants in Western blot analyses.
Expression of high molecular weight full-length LGCGR 
proteins is reduced in Down's syndrome pregnancies
In order to compare the LHCGR mRNA and protein
expression both mRNA and protein samples were
extracted from the same Trizol lysate. The LHCGR protein
expression in control and genetically compromised CVS
was examined by Western blot analysis and representative
data from such analyses are shown in Fig. 6.
The Mr 80–110K LHCGR protein isoforms are thought to
be the full-length functional receptor which is expressed
on the cell surface and has ligand binding and signal
transduction capacity [24,27]. In order to distinguish
between the expression of full-length and other LHCGR
isoforms, proteins in trisomic and normal CVS were
separated by extended electrophoresis and LHCGRPage 8 of 14
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The LHCGR extracellular domain (ECD) expressed in HEK-293 specifically reacted with human LHCGR 
mouse monoclonal antibody, LHR29. HEK 293 cells (expressing human LHCGR ECD, amino acid residues 1–362) were 
grown exponentially in tetracycline-free fetal bovine sera in the absence (lanes 1 and 3 in a and b, respectively) and in the pres-
ence of tetracycline (lanes 2 and 4 in a and b, respectively). Each lane contains 25 µg of total protein separated via electro-
phoresis through 8% polyacrlamide SDS gels. Blots were immuno-reacted with antibodies (lanes 3 and 4 of a and b, 
respectively). A shorter exposure of lane 4 (a) is shown on the right hand side of the Fig. 4a. Following chemiluminescence 
detection, blots were stained with coomassie brilliant blue (lanes 1 and 2 of a and b, respectively).
a
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visual examination of the blots shows that that the mature
isofoms (≥80K) were less abundant in DS CVS compared
to control pregnancies. Moreover, the stoichiometric yield
of the variants (Mr 44K-52K) in DS CVS (Fig. 6a) appears
to be distinctly different from that of control CVS (Fig.
6b). For direct comparison, the full-length functional iso-
form was quantified by densitometry of the Mr 80K bands
with respect to β-Actin expression in each lane. Each
sample including the reference in duplicate (control CVS
extracts) was analysed in at least two independent experi-
ments and the mean band density was used as a measure
of expression for each sample. Placental expression of
LHCGR (Mr 80 K) was lowest in DS (P<0.01), remained
unchanged in T13 and was marginally reduced (P<0.06)
in T18 CVS compared to that of control averages (Fig. 6c).
Serum hCG heterodimer levels negatively correlated (r = -
0.37) with LHCGR Mr 80 K protein expression in DS
pregnancies.
Discussion
In this study we have demonstrated that despite the high
concentrations of serum hCG heterodimer and hCG β in
DS pregnancies, their autocrine/paracrine effects on the
placenta may be severely impaired due to a reduced
expression of the hormone's cognate functional receptor.
The accumulation of high levels of serum hormone or
cytokine as a result of inadequate receptor-mediated sign-
aling is not unprecedented [34,35]. Serum concentrations
of IFN-γ are significantly higher in children suffering from
innocuous mycobacterial infection due to the inheritance
of non-functional IFN-γ R1 and 2 receptors [34,35]. Par-
tial or complete inactivation of the LHCGR gene due to a
naturally occurring somatic mutation within the coding
sequence could be responsible for the increase in serum
LH concentrations in leydig cell hypoplasia, male hypog-
onadism, and primary amenorrhea [49,50].
There are conflicting reports on the transcriptional regula-
tion of human hCG α and β mRNA in DS pregnancies. For
example, some studies suggest that the steady-state RNA
synthesis from the CGB gene in Down's syndrome and
At lease six LHCGR protein isoforms are expressed in human placentaFigure 5
At lease six LHCGR protein isoforms are expressed in human placenta. a) The HEK 293 (LHCGR ECD 1–362) cells 
grown in the absence (lane 1), in the presence of tetracycline (lane 2), 7 wk (lane 3) and 10 wk (lane 4) of gestation placental 
tissues were lysed with detergent (T-Per) and extracts (10 µg of protein in each lane) were immuno-reacted with LHR 29 anti-
body; b) Placental tissues (10–14 wks gestation) were extracted with Tri-zol reagents, proteins (10 µ/lane) were separated by 
extended electrophoresis in 8% SDS-PAGE and the blot was reacted with LHR29 antibody.
a bPage 10 of 14
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Reproductive Biology and Endocrinology 2005, 3:25 http://www.rbej.com/content/3/1/25The production of mature LHCGR isoforms in chorinic villi from Down's syndrome pregnancies are significantly reduced com-pared t  that of controlsFigure 6
The production of mature LHCGR isoforms in chorinic villi from Down's syndrome pregnancies are signifi-
cantly reduced compared to that of controls. The CVS samples were Tri-zol extracted to recover mRNA as well as pro-
teins. Approximately 10 µg of total protein was loaded in each lane. The proteins extracted from DS (T21) CVS (a) and control 
CVS (b) pregnancies were resolved in 8% polyacrylamide-SDS gels, Western blotted and immunoreacted with anti-human 
LHCGR (LHR-29) monoclonal antibody. Blots were stripped prior to immunostaining with anti-β-Actin monoclonal antibody. 
The data shown in a) and b) were from the same experiment except that the control and DS proteins were separated in two 
gels at the same time. In order to compare the band intensity in different experiments, two known CVS samples in duplicate 
were incorporated in each experiment. The density of the 80K LHCGR and 42K β-actin bands served as references for quan-
titative analysis of the experimental samples. The relative migration of the isoforms is indicated by an arrow. The Mr 80K pro-
tein band (LHCGR p80), indicated by * in a) and b), well separated from the neighboring variants were scanned and c) the 
relative densities of the LHCGR p80 with respect to β-Actin in normal and trisomic pregnancies, n = total number of experi-
ments carried out on protein samples in each condition. **P < 0.01.Page 11 of 14
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ble [51], while others show that the CGB gene is activated
[52,53] or repressed [54] in comparisons of in vitro cul-
tured trophoblasts from DS and control placenta.
The work presented here shows that when mRNA synthe-
sis is quantified for a large number of CVS samples (41),
the CGB (hCG β) gene in DS placenta is upregulated. This
suggests that the conflict between previous reports may be
due to sample size. In addition to this, the gestational age
of the DS placenta, as well as the methodology employed
by different laboratories to measure mRNA (northern
blotting and PCR), and to purify and in vitro culture of
cytotrophoblasts (CT) (discussed by Goshen [55]), could
have contributed to the conflicting results. Purified CTs or
placental explants have limited ability to differentiate
under normal O2 tension and exhibit an invasive pheno-
type in vitro [54,56-58]. Purified CTs cultured under 2%
O2 tension undergo a change into an invasive phenotype
[59]. Notably, differentiation also leads to the formation
of multinucleated giant cells instead of polarized epithe-
lial layers of ST (the major source of hCG β) with typical
microvillous structure and special antigen repertoire
(Susan Fisher, personal communication).
The steady state level of transcription (as measured by Q-
PCR of exons 1–5) from the LHCGR gene in DS was sig-
nificantly higher than that of control CVS, whereas, the
receptor expression in T18 and T13 pregnancies did not
significantly differ from that of gestation age-matched
control pregnancies (Fig. 2b). Nevertheless, a comparison
of the expression of exon 11 from control and DS CVS
indicated that a large proportion of the LHCGR transcripts
in DS CVS may not be full-length, since they did not con-
tain parts of exon 11. This might explain why up-regula-
tion of LHCGR mRNA (exon 1–5) did not correlate with
the expression of mature LHCGR p80 and other high Mr
isoforms which are less abundant in DS placenta (Figs. 2
and 6). These results also provide an explanation for pre-
viously reported increase in LHCGR mRNAs from T21 and
T18 pregnancies compared to controls where cDNA com-
mon to all spliced variants of LHCGR mRNAs was used as
an in situ hybridization probe on placental sections [60].
Interestingly, semi-quantitative PCR amplification of pla-
cental cDNA (LHCGR exons 9–11) and agarose gel analy-
sis revealed that truncated products were highly abundant
in late, compared to early, pregnancies (unpublished
data).
Our protein data differ from those of others [60] who
have demonstrated a significant increase in LHCGR pro-
tein in T21 and T18 placentas. However, this apparent
contradiction is reconciled by considering that immuno-
histochemical staining of tissue sections using a polyclo-
nal primary antibody raised against the common amino-
terminal 15–38 residues of the LHCGR peptide [60]
would stain both mature LHCGR and non-transducing
LHCGR isoforms produced from alternatively spliced
LHCGR mRNAs that have common N-terminal sequences
(Figure 2, and [20,21,42,43]). Therefore, immunohisto-
chemistry might be insufficient to distinguish mature
LHCGR from its truncated isoforms (Fig. 6).
Alternative promoter use [20,61], and differential splicing
of mRNA to produce various mRNA species [21,41-43,62]
and multiple protein isoforms (Figs. 5 and 6, and
[27,28,48]) are the hallmarks of molecular regulation of
the LHCGR gene. While our work implies that there could
be an increase in transcriptional initiation from the
LHCGR gene in DS placenta, further work is needed to
establish whether different promoters are utilized in DS
compared to physiologically normal pregnancies. This
could be important because in the transgenic mouse
model developed by Huhtaniemi's group [61] there
appears to be a link between alternative promoter utiliza-
tion and differential splicing in transgenes. It is interesting
to note that the multiple LHCGR protein isoforms (Figs. 5
and 6, and [28]) detected in placental extracts by Western
blot are also expressed in LH-induced human neuroblast-
oma cells [48]. How many of these isoforms are capable
of sequestering hCG by ligand binding is currently under
investigation.
The clinical relevance of this report stems from the signif-
icance of hCG in establishing and maintaining placental/
fetal development in human pregnancy. Given the recent
discovery of an unanticipated role for LH/hCG in the
distribution of cerebral blood flow [63], neurosteroido-
genesis and fetal development of sensory and autonomic
functions [64], the reduced expression of functional
LHCGR protein in placenta may have far-reaching conse-
quences. Indeed, the pathological activation of cerebral
microglial cells abundantly expressing LHCGR, has been
linked to Alzheimer's and other neurodegenerative dis-
eases with high circulating LH [48,65]. Some outstanding
questions remain to be answered, including whether the
reduced expression of the functional LHCGR isoforms in
placenta described here reflects a similar reduced expres-
sion in the fetal brain that might affect sensory and auto-
nomic development in DS babies, and whether the
reduction in functional LHCGR expression can be attrib-
uted to somatic mutations or an extra copy of chromo-
some 21.
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